Targeted thromboprophylaxis in ambulatory patients receiving anticancer therapies (TARGET-TP)

Interventions: Standard of care anticancer treatment plus enoxaparin thromboprophylaxis 40mg self-administered subcutaneously once daily for minimum 3 months, or until completion of anticancer therapy, to maximum 6 months (adherence monitored by drug returns).
Primary outcome(s): Objectively confirmed symptomatic or asymptomatic thromboembolism.
All thromboembolic events must be confirmed by appropriate standard diagnostic investigations such as radiological imaging for DVT or PE and cardiac investigations for suspected myocardial infarct. Study specific imaging will not be performed. A blinded clinical review panel will directly assess and review all radiological and cardiac investigations to confirm events. [At time of any routine imagining for cancer response or at clinical suspicion of thromboembolism, until six months after randomisation.
]
Study Design: Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Safety/efficacy